BiomX appoints Michael Oster as CEO, David Rokach as CFO

BiomX Inc. (NYSE American: PHGE) announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer, according to a company statement.

Oster brings experience in corporate strategy, mergers and acquisitions, and operational leadership across energy, infrastructure, and industrial sectors. He currently serves as CEO of Saffron Tech Ltd., an agritech company, and sits on the board of BladeRanger Ltd., a publicly traded Israeli drone payload systems company. Previously, Oster served as Senior Vice President of Mergers and Acquisitions at Alon USA Energy, Inc., leading strategic transactions during the company's growth as a publicly traded energy company with approximately $8 billion in revenue.

Rokach joins as Chief Financial Officer with more than two decades of experience in finance, investment management, and corporate leadership. He will oversee BiomX's financial strategy, capital markets activities, accounting, and investor relations. Rokach serves on the board of directors of T3 Defense Inc. since 2024 and previously served as Chief Executive Officer of Newcom Finance and Granit Investment Company.

"The company is entering an important phase as we evaluate business opportunities and continue executing on our development strategy," said Oster. "I look forward to working closely with our team to advance our programs, maintain disciplined execution, and deliver meaningful milestones that support long-term value for our shareholders."

Rokach stated his focus will be on supporting the company's strategy with disciplined financial management and strengthening engagement with the investment community.

BiomX is a clinical-stage company developing natural and engineered phage therapies designed to target harmful bacteria in chronic diseases.

You May Also Be Interested In

• MBX Biosciences names new CEO and CFO amid leadership shift
• Workhorse Group names Jody Davis as new CFO
• Mesoblast reaches 300-patient enrollment in back pain Phase 3 trial